Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: cytidine Clear all
Recruiting Phase 2 Interventional

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

NCT07043972
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Gemcitabine, Carboplatin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 23, 2026, 4:31 PM EDT
Recruiting Phase 1 Interventional

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
APVO436, Venetoclax, Azacitidine
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Denver, Colorado • Miami, Florida • Fairway, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 23, 2026, 4:31 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

NCT00907166
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Pancreatic Carcinoma
Interventions
CPI-613, Gemcitabine
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
The Bronx, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 23, 2026, 4:31 PM EDT
Recruiting Phase 2 Interventional

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

NCT03589729
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Myeloid Sarcoma, Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
Interventions
Cladribine, Cytarabine, Dexrazoxane Hydrochloride, Gemtuzumab Ozogamicin, Idarubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

NCT02472145
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Decitabine 20 mg/m^2, Talacotuzumab 9 mg/kg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000887
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nelfinavir mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
7
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 23, 2026, 4:31 PM EDT
Terminated Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00004093
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Gemcitabine, paclitaxel, vinorelbine, radiation therapy, Navelbine, Taxol
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

NCT00924898
View directory record Official record
Conditions
Acute HIV Infection, HIV Infections
Interventions
efavirenz, emtricitabine, and tenofovir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 23, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

NCT03386721
View directory record Official record
Conditions
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Interventions
simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Francisco, California • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 23, 2026, 4:31 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Drug Screening Using IMD in Bladder Cancer

NCT06204614
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 3 Interventional Results available

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Tarceva and Capecitabine for Pancreatic Cancer

NCT00125021
View directory record Official record
Conditions
Pancreatic Cancer, Neoplasm Metastasis
Interventions
Capecitabine, OSI-774
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 3 Interventional Results available

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

NCT00471146
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
AG-013736, Gemcitabine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Antioch, California • Corona, California • Glendora, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 23, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

NCT02341495
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Deferasirox, Cholecalciferol, Azacitidine
Drug
Lead sponsor
Elizabeth Henry
Other
Eligibility
65 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

NCT00992446
View directory record Official record
Conditions
Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine, Cytarabine, Etoposide, Melphalan, Rituximab, Vorinostat
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00003546
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 23, 2026, 4:31 PM EDT
Terminated Phase 2 Interventional Results available

AflacLL1901 (CHOA-AML)

NCT04326439
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML, Childhood
Interventions
Cytarabine, Daunorubicin, Erwinase, Etoposide, Gemtuzumab ozogamicin, Stem cell transplantation (SCT), Sorafenib
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

NCT01289457
View directory record Official record
Conditions
Leukemia
Interventions
Clofarabine, Idarubicin, Cytarabine, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 2 Interventional

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

NCT00276003
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Cancer
Interventions
Gemcitabine, Irinotecan, Allopurinol.
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00039403
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 23, 2026, 4:31 PM EDT
Not listed Phase 2 Interventional

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

NCT01513603
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia
Interventions
CLAG-M
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Sep 23, 2026, 4:31 PM EDT
Completed Phase 1 Interventional

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT00004862
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 23, 2026, 4:31 PM EDT
Terminated Phase 1 Interventional

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

NCT01886573
View directory record Official record
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Interventions
Azacitidine, Entinostat, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Lexington, Kentucky • Albuquerque, New Mexico • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 23, 2026, 4:31 PM EDT
Active, not recruiting Phase 1 Interventional

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686
View directory record Official record
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 4:31 PM EDT